You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Dosage effect of sorafenib in advanced hepatocellular carcinoma treatment
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HPS-068
- By: HU, Chun-Liang (Tainan Municipal Hospital, pharmacy)
- Co-author(s): Chun-Liang Hu: Department of pharmacy, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
Yang-Cheng Lee: Division of Hemato-Oncology, Department of Internal Medicine, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
Sheng-Kai Lin: Division of Community Service, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China - Abstract:
Background
Sorafenib, an oral multiple tyrosine kinase inhibitor, is the first-line therapy for advanced hepatocellular carcinoma (HCC). When standard dosage (800mg/day) provided, many patients required drug discontinuation or dose reduction due to adverse events (AEs). Some studies reported that starting with a lower sorafenib dose might lead to.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026